Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Duku peel ethyl acetate extract as an adjunctive treatment of doxorubicin on triple negative breast cancer 4T1 cells

Indonesian Journal of Biotechnology · Vol. 30 No. 1 (2025) · hlm. 39–46

DOI
10.22146/ijbiotech.102112
ISSN
2089-2241, 0853-8654
Terbit
2025-03-29
Penerbit
Universitas Gadjah Mada
Bahasa
eng
Lisensi
creativecommons.org/licenses/by-sa/4.0

Abstrak

Triple‐negative breast cancer (TNBC) faces significant treatment challenges due to its resistance to chemotherapy and high‐rate metastatic occurrence. Adjunctive treatment is a promising approach to improve chemotherapy effectiveness while reducing toxicity on normal cells. Natural compounds of Lansium domesticum (duku) exhibit potential as adjunctive cancer treatments. This study aims to investigate the potential of duku peel extract (DPE) to be developed as an adjunctive agent. The cytotoxic activity of DPE against 4T1 cells was conducted through MTT assay, both in single and combination treatments. The anti‐migratory effect of DPE was examined by scratch wound healing assay. The molecular mechanism of DPE was confirmed using virtual screening via bioinformatics approaches, including protein target prediction and molecular docking. The results show that DPE has cytotoxic activity with an IC50 value of 47 µg/mL against the 4T1 cell line, in a 24‐hour treatment period. Interestingly, DPE not only had a good synergistic effect (mean CI value, i.e. 0.34), but also showed significant inhibition of cell migration with doxorubicin (Dox). Additionally, virtual bioinformatics screening approaches suggest the potential mechanism of DPE compound action by targeting CDC25B and TOP2A. Overall, DPE holds promise as an adjunctive treatment of Dox against 4T1 TNBC cells.

Kata kunci

Jaringan kolaborasi para penulis

40 penulis · 136 tautan kepenulisan bersama · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • University of Brawijaya
  • IPB University
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Adam HermawanAfiliasi tidak diketahui21
Riris Istighfari JenieAfiliasi tidak diketahui20
Muthi’ IkawatiAfiliasi tidak diketahui16
Rohmad Yudi UtomoAfiliasi tidak diketahui9
Dyaningtyas Dewi Pamungkas PutriAfiliasi tidak diketahui8
Sri HandayaniUniversity of Brawijaya7
Sari HaryantiAfiliasi tidak diketahui5
Larasati LarasatiIPB University5
Dhania NovitasariAfiliasi tidak diketahui4
Retno MurwantiAfiliasi tidak diketahui4
Zalinar UdinAfiliasi tidak diketahui4
Indri KusharyantiAfiliasi tidak diketahui4
Ni Putu Linda LaksmianiAfiliasi tidak diketahui4
Ummi Maryam ZulfinAfiliasi tidak diketahui3
Anindyajati AnindyajatiAfiliasi tidak diketahui3
Erlina RivantiAfiliasi tidak diketahui3
Sendy JunediAfiliasi tidak diketahui3
Yogi ErtantoAfiliasi tidak diketahui3
Sofa FaridaAfiliasi tidak diketahui3
Fatiha Citra EffendiAfiliasi tidak diketahui3
Masashi KawaichiAfiliasi tidak diketahui2
Nunuk Aries NurulitaAfiliasi tidak diketahui2
Suwijiyo PramonoAfiliasi tidak diketahui2
Lailatul QodriaAfiliasi tidak diketahui2
Gergorius Gena MaranAfiliasi tidak diketahui2
Beni LestariAfiliasi tidak diketahui2
Asri Mega PutriAfiliasi tidak diketahui2
Hilyatul FadliyahAfiliasi tidak diketahui2
Yonika Arum LarasatiAfiliasi tidak diketahui2
Raditya Prima IstiajiAfiliasi tidak diketahui2
Nanda Resa PratamaAfiliasi tidak diketahui2
Nur Fitra SariAfiliasi tidak diketahui2
Raisatun Nisa SugiyantoAfiliasi tidak diketahui2
Yuni Fajar EstiAfiliasi tidak diketahui2

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) https://jurnal.ugm.ac.id/ijbiotech/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 8 Nov 2026.
Metadata asli (oai_dc) 
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">Duku peel ethyl acetate extract as an adjunctive treatment of doxorubicin on triple negative breast cancer 4T1 cells</dc:title>
	<dc:creator>Rahman, Faaza Aulia</dc:creator>
	<dc:creator>Septiani, Aulia Nur</dc:creator>
	<dc:creator>Rahmawati, Desty Restia</dc:creator>
	<dc:creator>Hapsari, Novia Permata</dc:creator>
	<dc:creator>Meiyanto, Edy</dc:creator>
	<dc:creator>Susidarti, Ratna Asmah</dc:creator>
	<dc:subject xml:lang="en-US">Adjunctive treatment; Bioinformatics; Lansium domesticum; Migration; TNBC</dc:subject>
	<dc:description xml:lang="en-US">Triple‐negative breast cancer (TNBC) faces significant treatment challenges due to its resistance to chemotherapy and high‐rate metastatic occurrence. Adjunctive treatment is a promising approach to improve chemotherapy effectiveness while reducing toxicity on normal cells. Natural compounds of Lansium domesticum (duku) exhibit potential as adjunctive cancer treatments. This study aims to investigate the potential of duku peel extract (DPE) to be developed as an adjunctive agent. The cytotoxic activity of DPE against 4T1 cells was conducted through MTT assay, both in single and combination treatments. The anti‐migratory effect of DPE was examined by scratch wound healing assay. The molecular mechanism of DPE was confirmed using virtual screening via bioinformatics approaches, including protein target prediction and molecular docking. The results show that DPE has cytotoxic activity with an IC50 value of 47 µg/mL against the 4T1 cell line, in a 24‐hour treatment period. Interestingly, DPE not only had a good synergistic effect (mean CI value, i.e. 0.34), but also showed significant inhibition of cell migration with doxorubicin (Dox). Additionally, virtual bioinformatics screening approaches suggest the potential mechanism of DPE compound action by targeting CDC25B and TOP2A. Overall, DPE holds promise as an adjunctive treatment of Dox against 4T1 TNBC cells.</dc:description>
	<dc:publisher xml:lang="en-US">Universitas Gadjah Mada</dc:publisher>
	<dc:contributor xml:lang="en-US">Gadjah Mada University</dc:contributor>
	<dc:date>2025-03-29</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en-US">Original Research Articles</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://journal.ugm.ac.id/ijbiotech/article/view/102112</dc:identifier>
	<dc:identifier>10.22146/ijbiotech.102112</dc:identifier>
	<dc:source xml:lang="en-US">Indonesian Journal of Biotechnology; Vol 30, No 1 (2025); 39–46</dc:source>
	<dc:source>2089-2241</dc:source>
	<dc:source>0853-8654</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://journal.ugm.ac.id/ijbiotech/article/view/102112/41319</dc:relation>
	<dc:relation>https://journal.ugm.ac.id/ijbiotech/article/downloadSuppFile/102112/35988</dc:relation>
	<dc:relation>https://journal.ugm.ac.id/ijbiotech/article/downloadSuppFile/102112/35989</dc:relation>
	<dc:relation>https://journal.ugm.ac.id/ijbiotech/article/downloadSuppFile/102112/35990</dc:relation>
	<dc:relation>https://journal.ugm.ac.id/ijbiotech/article/downloadSuppFile/102112/35991</dc:relation>
	<dc:relation>https://journal.ugm.ac.id/ijbiotech/article/downloadSuppFile/102112/35992</dc:relation>
	<dc:relation>https://journal.ugm.ac.id/ijbiotech/article/downloadSuppFile/102112/35995</dc:relation>
	<dc:relation>https://journal.ugm.ac.id/ijbiotech/article/downloadSuppFile/102112/36006</dc:relation>
	<dc:relation>https://journal.ugm.ac.id/ijbiotech/article/downloadSuppFile/102112/36007</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2025 The Author(s)</dc:rights>
	<dc:rights xml:lang="en-US">http://creativecommons.org/licenses/by-sa/4.0</dc:rights>
</oai_dc:dc>